SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as its community leverages high social engagement and steady, organic growth to push toward new market cap milestones. Supporters are actively discussing their long-term conviction in the project, emphasizing its transparency and community-driven approach as key differentiators in the memecoin market.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

The Buttcoin community is rallying behind a long-standing narrative that positions the token as a cultural counterpoint to traditional assets, driven by its 2011 origin story and status as an early pioneer in the parody coin space. Supporters are actively discussing a transition toward a more formal ecosystem, emphasizing the coin's historical persistence and growing adoption as primary catalysts for its future potential.

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

Ghost is trending as community members debate its potential as a privacy-focused utility token on the Solana network versus persistent accusations of it being a pump-and-dump scheme. Discussions are polarized between investors promoting it as an undervalued gem with upcoming project milestones and critics labeling it a slow rug pull.

Invitation Homes, Inc. engages in the acquisition, renovation, leasing, and operation of single-family homes as rental properties, including single-family homes in planned unit developments. Its services include property management, selection of homes, maintenance program, and online payment. The company was founded by Marcus Ridgway, Dallas Tanner, and Brad Greiwe in 2012 and is headquartered in Dallas, TX.

Invitation Homes Inc

Invitation Homes is garnering attention as the broader housing sector faces intense scrutiny over the impact of institutional ownership on home affordability. Investors are closely monitoring its performance against a backdrop of potential policy shifts, fluctuating interest rates, and internal growth initiatives like new development partnerships.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending due to anticipation of the CHOPIN trial data, which is set to be presented as a late-breaking abstract at ESMO. While the community is frustrated by recent stock volatility and revenue guidance adjustments, sentiment remains highly focused on the potential for clinical trial success to expand the Hepzato Kit's standard-of-care position and drive long-term value.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating intense community interest due to its ultra-low circulating supply and potential for price appreciation within the NFT and DeFi sectors. Investors are actively discussing the possibility of a supply shock and a significant breakout, with many advocating for accumulation despite recent volatility and skepticism.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as investors highlight the project's 'phygital' strategy, noting its physical presence in major retail stores and the recent launch of a Visa-backed spending card. Community sentiment remains polarized, with many holders aggressively accumulating during price dips while others express frustration over the token's inability to decouple from broader market volatility.

WorldFinancial

WorldFinancial (WLFI) is seeing intense volatility and social media debate as investors react to a Congressional probe into the projects foreign investment deals and ongoing concerns regarding governance and transparency. While some community members view the current price action as an accumulation opportunity ahead of upcoming crypto forums and product milestones, others remain highly skeptical, labeling the token a speculative grift that heavily relies on the Trump family brand.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending following an appeals court ruling that could significantly reduce its wildfire-related liabilities, while investors continue to debate the company's direction under new CEO Greg Abel. The community is actively discussing the stock's recent underperformance relative to the broader market, with many questioning the firm's capital allocation strategy and the long-term effectiveness of its massive cash pile.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

Aircoin is gaining significant traction on the Solana network, with the community highlighting its long-term project viability, consistent daily activity, and a voluntary supply-locking mechanism. Supporters are actively focused on the project's 'PvE' narrative, emphasizing deep conviction, doxxed leadership, and steady growth over short-term hype.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The study evaluated the device’s ability to detect codeine in 40 adults.</li><li>The company has begun the second phase of its program, which is expected to be completed by June 2026.</li><li>Intelligent Bio Solutions will also begin an Interference Study to evaluate how the device performs in real-world environments.</li></ul>Intelligent Bio Solutions (INBS) announced on Thursday the successful completion of its initial clinical study, which is needed to seek U.S. Food and Drug Administration (FDA) approval for its fingerprint-based drug testing system.Despite the seemingly positive update, <a href="https://stocktwits.com/symbol/INBS">INBS shares</a> slumped 10% on Thursday, following a 7% decline in the previous session.<h2 class="st-heading-2">What Was The Study About?</h2>The study evaluated the device’s ability to detect codeine in 40 adults and confirmed its accuracy using standard laboratory testing methods. INBS added that it has begun the second phase of its program, which it expects to complete by June 2026.Alongside the Method Comparison and Usability Study, the company will also begin an Interference Study to evaluate how the device performs when exposed to substances commonly found in real-world environments. The study is expected to be completed by the end of July 2026."The U.S. drug screening market is a significant commercial opportunity for Intelligent Bio Solutions. The on-schedule completion of our Cut-off Study validates our clinical approach and keeps us firmly on track toward our FDA 510(k) submission and planned commercial launch," said Harry Simeonidis, President and CEO at INBS.The company said its non-invasive fingerprint technology has advantages over traditional urine, oral fluid, and blood testing methods.&nbsp;Last week, the company received European Patent EP3752831, which relates to improving fingerprint chemical analysis by accounting for fingerprint deposition volume. This marks the company’s eighth European patent.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits remained 'bullish' over the past 24 hours, amid 'high' message volumes.One user said the stock will climb back up to $3 by Monday.<stembedurl>https://stocktwits.com/tommycman/message/649278493</stembedurl>Year-to-date, the stock has slumped more than 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

ZoomInfo said net revenue retention was stable for the third consecutive quarter. 

INBS Stock Falls After Clinical Study Win: FDA Progress Fails To Lift Shares 

The company completed its initial clinical study required for FDA approval of its fingerprint-based drug-testing system.

Equity

<ul class="summary-bullets"><li>The devices are being deployed across construction, transportation, logistics, and manufacturing sectors in the U.K. and Europe.</li><li>The company expects additional shipments in 2026 as it prepares for U.S. market entry.</li><li>Intelligent Bio Solutions expects to reduce annual production costs by more than 40%, which could lift gross margins by around 20 percentage points each year.</li></ul>Shares of Intelligent Bio Solutions Inc. (INBS) reversed their pre-market gains to trade 2% lower on Wednesday, after the company announced the rollout of the first shipment of its Intelligent Fingerprinting Drug Screening Readers produced under a new manufacturing partnership with Syrma Johari MedTech.The devices are being deployed across construction, transportation, logistics, and manufacturing sectors in the U.K. and Europe. Intelligent Bio Solutions also doubled its in-house production capacity for test strips. The company expects additional shipments in 2026 as it prepares for U.S. market entry.<h2 class="st-heading-2">Expanded Capacity To Boost Margins</h2>The company has added advanced manufacturing equipment, increasing its cartridge output, enabling Intelligent Bio Solutions to develop expanded drug-testing panels for different customer and regulatory needs.The medical technology company said its manufacturing capacity is now about four times higher than before. As a result, it expects to reduce annual production costs by more than 40%, which could lift gross margins by around 20 percentage points each year.“We are building a vertically integrated, cost-efficient manufacturing engine that supports margin expansion, accelerates innovation, and positions us to enter the U.S. market with operational strength and the capacity to grow with demand,” said Callistus Sequeira,&nbsp;VP of Global Quality &amp; Operations at Intelligent Bio Solutions.&nbsp;Earlier this month, INBS reported a 48% increase in second-quarter (Q2) revenue to $896,774, driven by a 104% surge in reader sales.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.&nbsp;Year-to-date, <a href="https://stocktwits.com/symbol/INBS">INBS stock</a> is down 47%For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

INBS Stock Reverses Early Gains After First Shipment of Drug Screening Readers Under Syrma Johari MedTech Partnership

The company announced the first shipment of its Intelligent Fingerprinting Drug Screening Readers, produced in collaboration with Syrma Johari MedTech.

<ul class="summary-bullets"><li>On Dec. 31, 2025, INBS stock closed over 132% after announcing a manufacturing partnership with Syrma Johari MedTech.</li><li>The company also announced a private placement with two healthcare-focused institutional investors to issue 2.3 million shares of common stock.</li><li>Intelligent Bio Solutions had announced a 1-for-10 reverse stock split effective Dec. 15.</li></ul>Shares of Intelligent Bio Solutions (INBS) have seen strong buying interest in recent weeks, with the stock adding more than 35% in premarket trading on Monday.&nbsp;From the close on Dec. 30, 2025, to Jan. 9, 2026, <a href="https://stocktwits.com/symbol/INBS">INBS stock</a> has surged about 337%, breaching both its 50-day moving average (50-DMA) and the longer-term 200-DMA during the rally.This stellar rally has made it a momentum favorite among retail traders, driven by a recent manufacturing partnership, fresh capital boost, and a compliance update with Nasdaq; however, concerns around dilution and its volatile ride continue to temper sentiment.&nbsp;<h2 class="st-heading-2">What Led To INBS Rally?</h2>On Dec. 31, 2025, INBS stock closed over 132% after announcing a manufacturing partnership with Syrma Johari MedTech to scale production of its fingerprint drug-screening reader. The deal is expected to cut annual production costs by over 40% and lift gross margins by about 20 percentage points, while expanding manufacturing capacity fourfold, Intelligent Bio Solutions said. The company said the deal positions it well for its U.S. market launch in 2026.The company also announced a private placement with two healthcare-focused institutional investors to issue 2.3 million shares of common stock along with Series K-1 and K-2 warrants for the same number of shares at $4.35 each, raising around $10 million before fees. The warrants have an exercise price of $4.10 per share.Separately, on January 7, Intelligent Bio Solutions was notified by Nasdaq that it had regained compliance to trade on the Nasdaq Capital Market. The closing bid price of INBS stock had remained at $1.00 or higher for 14 consecutive business days, from Dec. 16, 2025, to Jan. 6, 2026. The company had announced a 1-for-10 reverse stock split effective Dec. 15.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the bullish premarket movement, retail sentiment on Stocktwits remained in the ‘neutral’ zone over the past 24 hours. INBS was among the top-trending tickers on Stocktwits at the time of writing.One user thinks short interest is extremely high and predicts the stock could fall to $15. It is currently trading at $24.2.<stembedurl>https://stocktwits.com/Harsh1210/message/641505295</stembedurl>However, another user sees a setup that pits the company’s operational progress against short-term dilution fears.<stembedurl>https://stocktwits.com/Atdanaiw/message/641502687</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/silver-gold-record-highs-analyst-michael-oliver-predicts-500-breakout/cmU9UNvR4Ec">Silver’s Next Move Could Be Explosive: Michael Oliver Sees $200–$500 Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

INBS Stock Has Surged Over 330% So Far In January – But Retail Traders Are Warning Of A Pullback 

INBS shares were up more than 35% in premarket trading on Monday and were among the top trending tickers on Stocktwits.

INBS Stock Gains Triple-Digit Rally So Far In January: What’s Driving The Surge And What Traders Are Saying

Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session

INBS Stock Surges 132.4% on New Manufacturing Partnership 

Intelligent Bio Solutions' stock jumps after a new manufacturing partnership aimed at cutting costs, boosting margins and scaling production ahead of U.S. expansion.

Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026 Baidu, Rubico, Intelligent Bio Solutions In Focus

U.S. stock futures rose on the first trading day of the year on Friday after missing the Santa Claus rally over the truncated week. Futures of major benchmark indices were higher. The Santa Claus...

<ul class="summary-bullets"><li>Retail sentiment improved for SPY and QQQ on Stocktwits.</li><li>Traders are eyeing Tesla’s delivery data and a surge in silver prices.</li><li>Baidu drew retail attention after its chip unit filed for an IPO.</li></ul>U.S. stock futures were trading higher early Friday as markets reopened for the first full trading session of 2026. Wall Street is looking to break a three-year streak of opening-day losses. The S&amp;P 500 has had a negative close on its first trading day&nbsp;in each of the last three years (2023-2025).As of 2:50 a.m. ET on Friday, Nasdaq 100 futures were up 0.7%, S&amp;P 500 futures rose 0.4%, and the Dow futures gained 0.1%, while Russell 2000 futures rose 0.4%.On Stocktwits, the retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, moved to ‘bullish’ from ‘neutral’ a day ago. And sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bullish’, amid low message volumes.&nbsp;<h2 class="st-heading-2">Trending Stocks To Watch</h2> Baidu (BIDU): Trending following news that its chip unit filed for an IPO, sparking a renewed interest in ‘China AI’ discount plays. Tesla (TSLA): High search volume and social chatter ahead of its Q4 delivery report expected today. Meanwhile, reports suggest that China’s BYD has officially dethroned it as the global EV king for the full year 2025. NIO is trending high on Stocktwits as well.&nbsp; Watch out for&nbsp;iShares Silver Trust (SLV):&nbsp;Silver jumped 2.5% in early trading, building on its best annual performance since 1979.Stellantis (STLA): The company is resurrecting a gas-powered Ram pickup truck, the TRX, with a V-8 engine, as it faces fewer federal emissions regulations, CNBC reported.Other noteworthy tickers trending on Stocktwits at the time of writing were Intelligent Bio Solutions (INBS), BigBear.ai (BBAI), Corcept Therapeutics (CORT), and Sensei BioTherapeutics (SNSE).&nbsp;<h2 class="st-heading-2">Other Catalysts To Watch</h2>On the economic front, investors are looking ahead to the release of the Fed Balance Sheet (4:30 PM ET). Markets will be eyeing updates on ‘Quantitative Tightening’ (QT) pacing. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Point To Strong New-Year Open On Wall Street: Why TSLA, BIDU, SLV, STLA Are On Traders' Radar Today

Wall Street is hoping to break a three-year streak of opening-day losses.

Top Medical Stocks To Consider - January 1st

Eli Lilly and Company, UnitedHealth Group, Intelligent Bio Solutions, Johnson & Johnson, Merck & Co., Inc., Pfizer, and Corcept Therapeutics are the seven Medical stocks to watch today, according to...

Intelligent Bio Solutions Stock Surges 188% On New Manufacturing Partnership

(RTTNews) - Intelligent Bio Solutions Inc. (INBS) shares jumped 187.68%, trading at $11.80, up $7.70, after the company announced a new manufacturing partnership aimed at strengthening global...

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	--	-$3.60	--	N/A
Q3 '25	--	-$0.44	--	N/A
Q2 '25	--	-$0.50	--	N/A
Q1 '25	--	-$0.70	--	N/A
Q4 '24	-$5.10	$9.60	288.24%	BEAT

INBS
Intelligent Bio Solutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest INBS News

INBSIntelligent Bio Solutions Inc